Genetic prediction of coronary heart disease: Lessons from Canada

Scandinavian Journal of Clinical and Laboratory Investigation, Supplement

Volumn 59, Issue 230, 1999, Pages 153-167

  Hegele, Robert A ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Atherosclerosis; Diabetes; Lipids; Obesity; Polygenic disease

Indexed keywords

ANGIOTENSINOGEN; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; BLOOD CLOTTING FACTOR 5; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CANADA; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE ASSOCIATION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; ISCHEMIC HEART DISEASE; OBESITY; PRIORITY JOURNAL; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; FAMILY HEALTH; GENETIC SCREENING; GENETICS; PREDICTION AND FORECASTING; REVIEW; RISK FACTOR;

CANADA; CORONARY DISEASE; DISEASE SUSCEPTIBILITY; FAMILY HEALTH; GENETIC SCREENING; HUMANS; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 0032610973     PISSN: 0085591X     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365519909168339     Document Type: Conference Paper

References (69)

1. Healthy people 2000: National health promotion and disease prevention objectives. US Department of Health and Human Services publication (PHS) 91-50212; Hyattsville MD, 1990.
2. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998;140:199-270.
3. Cheng S, Pallaud C, Grow MA, Scharf SJ, Erlich HA, Klitz W, Pullinger CR, Malloy MJ, Kane JP, Siest G, Visvikis S. A multilocus genotyping assay for cardiovascular disease. Clin Chem Lab Med 1998; 36:561-6.
4. Report of a WHO consultation on familial hypercholesterolemia. Paris, 1997, WHO/FGN/FH/WG/98.7
5. Marenberg ME, Risch N, Berman LF, Floderus B, deFaire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330:1041-1046.
6. Strong JP. Atherosclerotic lesions: natural history, risk factors and topography. Arch Path Lab Med 1992; 116:1268-1275.
7. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326:242-354.
8. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature 1993; 362:801-809.
9. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
10. Sing CF, Haviland MB, Templeton AR, Reilly SL. Alternative genetic strategies for predicting risk of atherosclerosis. In Woodford FP, Davignon J, Sniderman AD (eds) Atherosclerosis X Elsevier Science BV; 1995: 638-644.
11. Hegele RA. Candidate genes, small effects, and the prediction of atherosclerosis. Crit Rev Clin Lab Sci 1997; 34:343-67.
12. Hegele RA. Small genetic effects in complex diseases: a review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis. Clin Biochem 1997;30:183-8.
13. Hegele RA. The genetic basis of atherosclerosis. Int J Clin Lab Res 1997;27:2-13.
14. Lander ES, Schork N. Genetic dissection of complex traits. Science 1994; 265:2037-2048.
15. Goldstein JL, Brown MS. The clinical investigator: bewitched, bothered, and bewildered - but still beloved. J Clin Invest 1997; 99:2803-2812.
16. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 1996;16:1250-5.
17. Siest G, Pillot T, Regis-Bailly A, Leininger-Muller B, Steinmetz J, Galteau MM, Visvikis S. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem 1995;41:1068-86.
18. Butler R, Morris AD, Struthers AD. Angiotensin-converting enzyme gene polymorphism and cardiovascular disease. Clin Sci (Colch) 1997; 93:391-400.
19. O'Dell SD, Humphries SE, Day IN. Rapid methods for population-scale analysis for gene polymorphisms: the ACE gene as an example. Br Heart J 1995; 73:368-71.
20. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet 1996;58:1268-78.
21. Scanu AM, Fless GM. Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest 1990; 85:1709-1715.
22. Hegele RA, Brunt JH, Connelly PW. Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. Arterioscler Thromb Vasc Biol 1995; 15:861-871.
23. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the angiotensinogen gene associated with variation in blood pressure in a genetic isolate. Circulation 1994; 90:2207-2212.
24. Hegele RA, Brunt JH, Connelly PW. Genetic variation on chromosome 1 associated with variation in body fat distribution in men. Circulation 1995; 92:1089-1093.
25. Hegele RA, Harris SB, Hanley AJ, Sadikian S, Connelly PW, Zinman B. Genetic variation of intestinal fatty acid-binding protein associated with variation in body mass in aboriginal Canadians. J Clin Endocrinol Metab 1996; 81:4334-4337.
26. Hegele RA, Connelly PW, Scherer SW, Hanley AJ, Harris SB, Tsui LC, Zinman B. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82:3373-3377.
27. Hegele RA, Connelly PW, Scherer SW, Hanley AJ, Harris SB, Tsui LC, Zinman B. Paraoxonase-2 G148 variant in an aboriginal Canadian girl with non-insulin-dependent diabetes. Lancet 1997; 350:785.
28. Hegele RA, Harris SB, Zinman B. Hemochromatosis and diabetes mellitus. Ann Intern Med 1998; 129:587.
29. Hegele RA, Harris SB, Hanley AJ, Azouz H, Connelly PW, Zinman B. Absence of association between genetic variation of the beta 3-adrenergic receptor and metabolic phenotypes in Oji-Cree. Diabetes Care 1998; 21:851-854.
30. Hegele RA, Harris SB, Zinman B, Wang J, Cao H, Hanley AJ, Tsui LC, Scherer SW. Variation in the AU(AT)-rich element within the 3′-untranslated region of PPP1R3 is associated with variation in plasma glucose in aboriginal Canadians. J Clin Endocrinol Metab 1998;83:3980-3983.
31. Hegele RA, Zinman B, Hanley AJ, Harris S, Connelly PW. A common mtDNA polymorphism associated with variation in plasma triglyceride concentration. Am J Hum Genet 1997; 60:1552-1555.
32. Hegele RA, Connelly PW, Hanley AJ, Sun F, Harris SB, Zinman B. Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians. Arterioscler Thromb Vasc Biol 1997; 17:1060-1066.
33. Hegele RA, Connelly PW, Hanley AJ, Sun F, Harris SB, Zinman B. Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler Thromb Vasc Biol 1997;17:2753-2758.
34. Hegele RA, Harris SB, Connelly PW, Hanley AJ, Tsui LC, Zinman B, Scherer SW. Genetic variation in paraoxonase-2 is associated with variation in plasma lipoproteins in Canadian Oji-Cree. Clin Genet 1998; 54:394-399.
35. Hegele RA, Harris SB, Hanley AJ, Sun F, Connelly PW, Zinman B. Angiotensinogen gene variation associated with variation in blood pressure in aboriginal Canadians. Hypertension 1997; 29:1073-1077.
36. Hegele RA, Harris SB, Hanley AJ, Sun F, Connelly PW, Zinman B. -6A promoter variant of angiotensinogen and blood pressure variation in Canadian Oji-Cree. J Hum Genet 1998;43:37-41.
37. Hegele RA, Harris SB, Hanley AJ, Cao H, Zinman B. G protein beta3 subunit gene variant and blood pressure variation in Canadian Oji-Cree. Hypertension 1998; 32:688-692.
38. Hegele RA, Harris SB, Cao H, Hanley AJ, Zinman B. Factor V Leiden (F5 Q506) and vascular disease in Canadian Oji-Cree. Diabetes Care 1998; 21:1203.
39. Hegele RA, Wolever TM, Hanley AJ, Harris SB, Zinman B. Methylenetetrahydrofolate reductase gene, dietary folate, NIDDM, and atherosclerosis in Canadian Oji-Cree. Diabetes Care 1998;21:322-323.
40. Hegele RA, Harris SB, Zinman B, Hanley AJG, Connelly PW. Increased plasma apolipoprotein B-containing lipoproteins associated with increased urinary albumin within the microalbuminuria range in type 2 diabetes. Clin Biochem, 1999, in press.
41. Hegele RA, Harris SB, Hanley AJG, Zinman B. Association between AGT T235 variant and microalbuminuria in Canadian Oji-Cree with type 2 diabetes mellitus. Clin Biochem 1999, in press.
42. Hegele RA, Sun F, Harris SB, Anderson C, Hanley AJG, Zinman B. Genome-wide scanning for type 2 diabetes susceptibility in Canadian Oji-Cree using 190 microsatellite markers. J Hum Genet 1999; 44:10-14.
43. Hegele RA, Cao H, Harris SB, Hanley AJG, Zinman B. HNF-1a G319S: a private mutation in Oji-Cree associated with type 2 diabetes. Diabetes Care 1999, in press.
44. Hegele RA, Cao H, Harris SB, Hanley AJ, Zinman B. The hepatic nuclear factor-1 G3 19S variant is associated with early onset type 2 diabetes in Canadian Oji-Cree. J Clin Endo Metab 1999, in press.
45. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77:1179-84.
46. Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study. Lancet 1994; 344:1383-1389.
47. Williams RR, Hasstedt SJ, Wilson DE, Ash KO, Yanowitz FF, Reiber GE, Kuida H. Evidence that med with familial hypercholesterolemia can avoid early death. An analysis of 77 gene carriers in four Utah pedigrees. JAMA 1986; 255:219-224.
48. Hegele RA, Emi M, Wu LL, Hopkins PN, Williams RR, Lalouel JM. Clinical application of deoxyribonucleic acid markers in a Utah family with hypercholesterolemia. Am J Cardiol 1989; 63:109-112.
49. Breslow JL. Familial disorders of high density lipoprotein metabolism. In: Scriver CR, Beardet AL, Sly WS, Valle D; eds. The Metabolic Basis of Inherited Diseases. New York: McGraw Hill Inc; 1989:1251-66.
50. Assmann G, Schmitz G, Brewer HB Jr. Familial high density lipoprotein deficiency: Tangier disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D; eds. The Metabolic Basis of Inherited Diseases. New York: McGraw Hill Inc; 1989:1267-82.
51. Funke H and Assmann G. The lowdown on lipoprotein lipase. Nat Genet 1995; 10:6-7.
52. Ng DS, Leiter LA, Vezina C, Connelly PW, Hegele RA. Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest 1994;93:223-9.
53. Anderson KM, Wilson PW, Odell PM , Kannel WB. An updated coronary risk profile. Circulation 1991; 83:866-74.
54. Young TK, Moffatt ME, O'Neil JD. Cardiovascular diseases in a Canadian Arctic population. Am J Public Health 1993; 83:881-887.
55. Young TK. Chronic diseases among Canadian Indians: towards an epidemiology of culture change. Arctic Med Res 1988; 47: 434-441.
56. Moffatt MEK, Young TK, O'Neil JD et al. The Keewatin Health Assessment Study. Arctic Med Res 1993; 52: 18-21.
57. Young TK, Nikitin YP, Shubinov EV, Astakhova TI, Moffatt MEK, O'Neil JD. Plasma lipids in two indigenous arctic populations with low risk for cardiovascular diseases. Am J Hum Biol 1995; 7:223-236.
58. Hegele RA, Young TK, & Connelly PW. Are Canadian Inuit at increased genetic risk for coronary heart disease? J Mol Med 1997; 75:364-370.
59. Hegele RA, Tully C, Young TK, Connelly PW. V677 mutation of methylenetetra-hydrofolate reductase and cardiovascular disease in Canadian Inuit. Lancet 1997; 349:1221-1222.
60. Price DR, Ridker PM: Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Int Med 1997; 127:895-903.
61. Guerra R, Wang J, Grundy SM, Cohen JC. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci USA 1997; 94:4532-4537.
62. Xia J, Scherer SW, Cohen PTW, Majer M, Norman RA, Knowler WC, Bogardus C, Prochazka M. A common variant in PPPIR3 contributes to insulin resistance and type-2 diabetes. Diabetes 1998; 47:1519-1524.
63. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJH. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34:275-278.
64. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995; 96:2601-2605.
65. Young TK. Obesity, central fat patterning and their metabolic correlates among the inuit of the central arctic. Hum Biol 1996; 68: 245-263.
66. Shah B, Hux J, Zinman B. Increasing incidence of ischemic heart disease among aboriginals in Northern Ontario. Can J Diab Care 1998; 22:A8
67. Young TK, Szathmary EJ, Evers S, Wheatley B. Geographical distribution of diabetes among the native population of Canada: a national survey. Soc Sci Med 1990; 129-139.
68. Harris SB, Gittelsohn J, Hanley AJG, Barnie A, Wolever TMS, Gao J, Logan A, Zinman B: The prevalence of NIDDM and associated risk factors in native Canadians. Diabetes Care 1997; 20:185-197.
69. Neel JV. The genetics of diabetes mellitus. In Early Diabetes. Camerini-Davalos R, Cole HS (eds) 1970. Academic Press, Inc., Orlando, FLA, pp 3-10.